AstraZeneca's Lynparza Gets Approval In Japan To Treat Three Cancers
AstraZeneca's Lynparza Gets Approval In Japan To Treat Three Cancers Mon, 28th Dec 2020 08:05 (Alliance News) - AstraZeneca PLC said Monday its Lynparza cancer treatment has secured approval in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers. Astra jointly develops and commercialises the drug with US pharmaceutical company Merck & Co Inc. The pair signed a global strategic oncology collaboration to co-develop and co-commercialise Lynparza in July 2017. The concurrent approvals by the Japanese Ministry of Health, Labour & Welfare are based on positive results from...